Human Interleukin-13 Recombinant

/, Recombinant Human Cytokines/Human Interleukin-13 Recombinant

Human Interleukin-13 Recombinant


accession P35225

Source Optimized DNA sequence encoding Human Interleukin-13 mature chain was expressed in Escherichia Coli.
Molecular weight Nativehuman Interleukin-13, generated by the proteolytic removal of the signal peptideand propeptide, the molecule has a calculated molecular mass of approximately13 kDa. Recombinant IL-13 is a monomer protein consisting of 115 amino acid residue subunits,and migrates as an approximately 13 kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity >95%, as determined by SDS-PAGE and HPLC
Biological Activity The ED(50) was determined by the dose-dependent proliferation of TF-1 cells was ≤0.1 ng/ml, corresponding to a specific activity of ≥ 1x10 7 units/mg.
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
Presentation Recombinant Interleukin-13 was lyophilized from a 0.2μm filtered concentrated (1mg/ml) solution in PBS, pH.2.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Interactor P24394 IL4RA_HUMAN
Interactor P78552 I13R1_HUMAN
Interactor Q14627 I13R2_HUMAN
Molecular function Cytokine


LMWHA inhibits IL-4 or IL-13-induced fibrocyte differentiation.

recombinant human IL-13
  • Human PBMC were cultured in SFM, SFM with 1 ng/ml IL-4, SFM with 300 µg/ml LMWHA, or SFM with 1 ng/ml IL-4 and 300 µg/ml LMWHA, or SFM, SFM with 1 ng/ml IL-13, or SFM with 1 ng/ml IL-13 and 300 µg/ml LMWHA.

Expression of markers for M2-type macrophages in phorbol 12-myristate 13-acetate (PMA)-treated THP-1 macrophages.

20 ng/mL IL-13
  • THP-1 cells treated with 320 nM PMA for 4 h, and then cultured with PMA plus 20 ng/mL interleukin -4 and 20 ng/mL IL-13 for another 20 h had significantly higher mRNA expressions of CD36 and CD163 (both markers of M2 macrophages) compared to those of M1-polarized THP-1 macrophages.

Generation of CD163-positive M2 macrophages by IL-8.

recombinant human IL-13
  • Healthy donor-derived monocytes were treated with M-CSF (25 ng/ml) for 5 days and then IL-4 (20 ng/ml) and IL-13 (20 ng/ml) for 2 days, or with M-CSF (25 ng/ml) for 5 days and then IL-8 (10 ng/ml) for 2 days.

Kinetics of IL-13 response in TE-7 epithelial cells In A, the heat map represents hierarchical clustering of the fold change difference of 767 genes significantly altered by IL-13 treatment in the TE-7 cell line compared to untreated control (DESeq p < 0.05).

  • In B, the Venn diagram shows the overlap of genes significantly affected by IL-13 in TE-7 cells at all assessed time points and genes differentially expressed in human esophageal biopsies of patients with active EoE (p < 0.05).